[1} Announces The Launch Of GLYDO™ (Lidocaine HCI Jelly USP, 2%)
Published: Jun 19, 2014
SCHAUMBURG, Ill., Sept. 26, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the launch of GLYDO™ (lidocaine HCI jelly USP, 2%), Sagent's new branded drug offering. GLYDO is a topical urological anesthetic lubricant available in prefilled, ready-to-use, disposable plastic syringes in two unique sizes—6 mL and 11 mL. GLYDO syringes are individually packaged and sterilized, allowing GLYDO to be used during surgical procedures while maintaining the integrity of the sterile field.
According to IMS, for the 12 months ending July 2014, the U.S. market for lidocaine HCI jelly, 2% is approximated at $30 million. As with all products in Sagent's portfolio, GLYDO features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
"Sagent is proud to offer GLYDO, a sterile urological anesthetic lubricant, to the U.S. market. GLYDO is provided in a novel prefilled syringe, designed by urologists specifically for the urology market, which is used in over 40 countries, with more than 500 million applications," said Jeffrey M. Yordon, Chief Executive Officer and Chairman of the Board.
About GLYDO (lidocaine HCI jelly, USP 2%)
GLYDO (lidocaine HCI jelly USP, 2%) is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal).
The package insert, available at www.sagentpharma.com, contains the indications, complete side effect profile, and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 email@example.com